文献速递浆细胞疾病

流式细胞术与功能影像联合用于骨髓瘤残留病监测

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.
PubMed 文献 · Leukemia · 2018-12-20

该研究纳入一线或挽救治疗达完全缓解(CR)的多发性骨髓瘤(MM)患者,在CR时行微小残留病(MRD)流式细胞术及正电子发射断层扫描(PET)与弥散加权磁共振成像(DW-MRI)。残留局灶病变(FLs)在一线患者中可检出24%,与无进展生存期(PFS)短相关,DW-MRI检出更多患者;部分患者FLs仅PET阳性,提示两种影像互补。联合MRD与影像可改善预后预测,双阴性与双阳性分别定义PFS极佳与极差组。

要点

  • 一线CR患者中24%可检出残留局灶病变(FLs),与PFS短相关,DW-MRI较PET检出更多患者。
  • 部分患者FLs仅PET阳性,提示PET与DW-MRI两种影像方法互补。
  • 联合MRD与影像可改善预后预测:双阴性组PFS极佳,双阳性组PFS极差。

核心结论

  • DW-MRI是监测残留病的有前景工具,可补充PET,并应与MRD联合应用。

研究设计与样本

  • 研究纳入一线或挽救治疗达完全缓解(CR)的多发性骨髓瘤(MM)患者,在CR时行MRD流式细胞术及PET与DW-MRI两种影像检查。

主要发现

  • 一线患者中24%可检出残留局灶病变(FLs),与无进展生存期(PFS)短相关,DW-MRI较PET检出更多患者。
  • 部分患者FLs仅PET阳性,提示两种影像方法互补。
  • 联合MRD与影像可改善预后预测,双阴性组PFS极佳,双阳性组PFS极差。
  • 一线MRD阴性CR患者中FLs为罕见事件(12%),而挽救治疗达MRD阴性CR患者中FLs常见(50%)。
  • 一名MRD阴性患者的多区域测序与影像显示空间分离的克隆持续存在。

临床怎么用

  • 作者认为DW-MRI是监测残留病的有前景工具,可补充PET,并应与MRD联合应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The iliac crest is the sampling site for minimal residual disease (MRD) monitoring in multiple myeloma (MM). However, the disease distribution is often heterogeneous, and imaging can be used to complement MRD detection at a single site. We have investigated patients in complete remission (CR) during first-line or salvage therapy for whom MRD flow cytometry and the two imaging modalities positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging (DW-MRI) were performed at the onset of CR. Residual focal lesions (FLs), detectable in 24% of first-line patients, were associated with short progression-free survival (PFS), with DW-MRI detecting disease in more patients. In some patients, FLs were only PET positive, indicating that the two approaches are complementary. Combining MRD and imaging improved prediction of outcome, with double-negative and double-positive features defining groups with excellent and dismal PFS, respectively. FLs were a rare event (12%) in first-line MRD-negative CR patients. In contrast, patients achieving an MRD-negative CR during salvage therapy frequently had FLs (50%). Multi-region sequencing and imaging in an MRD-negative patient showed persistence of spatially separated clones. In conclusion, we show that DW-MRI is a promising tool for monitoring residual disease that complements PET and should be combined with MRD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2018. PMID: 30573775. doi:10.1038/s41375-018-0329-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。